Impakter
  • FINANCE
    • ESG News
    • Sustainable Finance
    • Business
  • TECH
    • Start-up
    • AI & Machine Learning
    • Green Tech
  • Environment
    • Biodiversity
    • Climate Change
    • Circular Economy
    • Energy
  • Industry News
    • Entertainment
    • Fashion & Lifestyle
    • Food and Agriculture
    • Health
    • Politics & Foreign Affairs
    • Philanthropy
    • Science
    • Sport
  • Editorial Series
    • SDGs Series
    • Shape Your Future
    • Sustainable Cities
      • Copenhagen
      • San Francisco
      • Seattle
      • Sydney
  • About us
    • Company
    • Team
    • Global Leaders
    • Partners
    • Write for Impakter
    • Contact Us
    • Privacy Policy
No Result
View All Result
  • FINANCE
    • ESG News
    • Sustainable Finance
    • Business
  • TECH
    • Start-up
    • AI & Machine Learning
    • Green Tech
  • Environment
    • Biodiversity
    • Climate Change
    • Circular Economy
    • Energy
  • Industry News
    • Entertainment
    • Fashion & Lifestyle
    • Food and Agriculture
    • Health
    • Politics & Foreign Affairs
    • Philanthropy
    • Science
    • Sport
  • Editorial Series
    • SDGs Series
    • Shape Your Future
    • Sustainable Cities
      • Copenhagen
      • San Francisco
      • Seattle
      • Sydney
  • About us
    • Company
    • Team
    • Global Leaders
    • Partners
    • Write for Impakter
    • Contact Us
    • Privacy Policy
No Result
View All Result
Impakter
No Result
View All Result
Home Society Health

Qnovia Raises $17 M to Fight Nicotine Addiction

The Richmond-based startup is looking to launch its RespirRx device that could deliver nicotine replacement therapy

byAlessandro du Besse' - Tech Editor
October 3, 2022
in Health, Start-up, Tech
Share on FacebookShare on Twitter

Medtech and pharmaceutical company Qnovia just completed a $17 Million Series A round led by Blue Ledge Capital. Other investors in this round include DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures.

Qnovia developed an innovative inhaler that could effectively operate in any position when used by a patient. The company is now looking for an application of this device in the NRT – nicotine replacement therapy – market.

The Richmond-based MedTech company that recently rebranded from its original name Respira Technologies, Inc. has also just appointed a new CEO, Brian Quigley. Quigley is an expert in this sector having spent sixteen years at Altria Group, the last seven leading the smokeless and innovative product development of the brand.


RELATED ARTICLES: Tozero raises € 3.5 M to take battery recycling to the next level in Europe | SiTration Raises $2.3M To Further Develop Its Battery Recycling Technology | Tesseract Raises $78M to Facilitate Access to Clean Energy |

The RespiRx is a portable handheld device and the company believes it could be a game changer in the treatment of nicotine addiction. According to Qnovia, RespirRx is able to deliver a nicotine hit quicker than any other device or alternative method.

Thanks to RespiRx users will be able to manage better their nicotine withdrawals and hopefully, this will help them quit smoking.

In order to bring RespiRx to the market, Qnovia will first be seeking FDA approval for their NRT treatment. Once that is achieved, the company will start phase one of the research study.

As reported by the American Cancer Society, NRT could be a very effective method to help people quit smoking. The only issue with NRT is that it could only replace the physical need for nicotine. To be able to quit smoking, psychological support might be needed as well.

It is a crucial moment for the NRT industry. According to a recent study, the market is expected to grow by 15% until 2028. There are other startups as well as major pharmaceutical companies that are working on other NRT treatments.

Considering that smoking causes every year almost 500,000 deaths just in the USA, looking for solutions to reduce smoking and nicotine addiction is critical. Will the RespiRx become an alternative to patches, gums, or nasal inhalers? The process to get to the market might be long but there is definitely a space in the market for this solution.


Editor’s Note: The opinions expressed here by Impakter.com columnists are their own, not those of Impakter.com
In the cover picture: A woman Smoking. Cover photo credit: Unsplash.

Tags: AddictionHealthcarehealthtechmedtechnicotineQnoviaRespirRxsmoking
Previous Post

Seven Steps Towards the Eradication of World Hunger

Next Post

Cuba Legalises Same-Sex Marriage, but Is There Still a Cloud Over the Rainbow?

Alessandro du Besse' - Tech Editor

Alessandro du Besse' - Tech Editor

Alessandro is the General Manager of ImpakterUP and the Tech Editor of Impakter. He joined Impakter in 2016 after working in the field of privacy law. Alessandro is a Law (Italy) and Political Science graduate (USA) and has always been interested in tech solutions that could help the environment.

Related Posts

Under the current crypto market landscape, questions are raised on the ethical correctness of crypto
Business

Is Crypto Corrupt?

May 15, 2025
boom overture supersonic jet
Business

Supersonic Renaissance: Can Speed and Sustainability Coexist?

May 14, 2025
vaccines dementia
Health

Could Vaccines for Viruses Lower the Risk of Dementia?

May 5, 2025
Next Post
cuba same-sex marriage

Cuba Legalises Same-Sex Marriage, but Is There Still a Cloud Over the Rainbow?

Recent News

ESG News regarding Intel Challenges €376 Million EU Fine Over Anti-Competitive Practices

Intel Fights €376 Million Antitrust Fine over Market Practices

May 16, 2025
US President Donald Trump

Trump Is the Symptom of Deeper American Malaise

May 16, 2025
EU and China strengthen sustainable finance ties amid geopolitical tensions.

The Great Recalibration: EU and China Talk Green Money

May 16, 2025

Impakter informs you through the ESG news site and empowers your business CSRD compliance and ESG compliance with its Klimado SaaS ESG assessment tool marketplace that can be found on: www.klimado.com

Registered Office Address

Klimado GmbH
Niddastrasse 63,

60329, Frankfurt am Main, Germany


IMPAKTER is a Klimado GmbH website

Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).


Office Hours - Monday to Friday

9.30am - 5.00pm CEST


Email

stories [at] impakter.com

By Audience

  • TECH
    • Start-up
    • AI & MACHINE LEARNING
    • Green Tech
  • ENVIRONMENT
    • Biodiversity
    • Energy
    • Circular Economy
    • Climate Change
  • INDUSTRY NEWS
    • Entertainment
    • Fashion & Lifestyle
    • Food and Agriculture
    • Health
    • Politics & Foreign Affairs
    • Philanthropy
    • Science
    • Sport
    • Editorial Series

ESG/Finance Daily

  • ESG News
  • Sustainable Finance
  • Business

Klimado Platform

  • Klimado ESG Tool
  • Impakter News

About Us

  • Team
  • Global Leaders
  • Partners
  • Write for Impakter
  • Contact Us
  • Privacy Policy

© 2025 IMPAKTER. All rights reserved.

No Result
View All Result
  • FINANCE
    • ESG News
    • Sustainable Finance
    • Business
  • TECH
    • Start-up
    • AI & Machine Learning
    • Green Tech
  • Environment
    • Biodiversity
    • Climate Change
    • Circular Economy
    • Energy
  • Industry News
    • Entertainment
    • Fashion & Lifestyle
    • Food and Agriculture
    • Health
    • Politics & Foreign Affairs
    • Philanthropy
    • Science
    • Sport
  • Editorial Series
    • SDGs Series
    • Shape Your Future
    • Sustainable Cities
      • Copenhagen
      • San Francisco
      • Seattle
      • Sydney
  • About us
    • Company
    • Team
    • Global Leaders
    • Partners
    • Write for Impakter
    • Contact Us
    • Privacy Policy

© 2024 IMPAKTER. All rights reserved.